alexa New Techniques And Approaches To Address The Drugability Of RNA | 10157
ISSN: 2155-9872

Journal of Analytical & Bioanalytical Techniques
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Recommended Conferences
Share This Page

New techniques and approaches to address the drugability of RNA

4th International Conference and Exhibition on Analytical & Bioanalytical Techniques

Jonathan Hall

ScientificTracks Abstracts: J Anal Bioanal Tech

DOI: 10.4172/2155-9872.S1.013

Abstract
The development of new tools in chemical biology can lead to significant advances in biology. Nowhere is this more prominent than in the chemistry of oligoribonucleotides. Examples of such tools include very long structured RNAs, modified RNAs for screening, RNAs site-specifically labeled with functional groups, siRNAs, miRNA mimics and anti-microRNA oligonucleotides as genetic tools. Techniques for the modification and functionalization of RNA can be of paramount importance in the emerging field of RNA-related biomedical research. A variety of labels and functional groups have been developed in order to study a wide array of RNA properties and functions, including RNA-RNA and RNA-protein interactions suspected of playing roles in pathological mechanisms. In a program designed to advance the drugability of RNA we have developed new chemical approaches to identify the cellular partners of coding and non-coding RNAs, as well as new in vitro assays to characterize ligand-RNA interaction. We are using these tools and assays to design new classes of ligands that modulate the functions of selected RNAs in pathological mechanisms. Examples will be presented.
Biography
Jonathan Hall is Professor for Pharmaceutical Chemistry at the ETH Zurich since 2007, and is currently Chair of the Institute. He is a chemist with a broad experience in the chemistry and biology of nucleic acids. He worked for fifteen years at Novartis Pharmaceuticals where he led a nucleic acids group. His interests lie with the discovery of RNA targets in disease pathways and the development of new chemistry to inhibit RNA function, in particular the inhibition of non-coding RNA biogenesis.
Top